NCT03375606 is a Phase 1 clinical trial of CSL730 in Healthy, sponsored by CSL Behring.

Who is sponsoring NCT03375606?

NCT03375606 is sponsored by CSL Behring.

What drugs are being tested in NCT03375606?

Interventions in NCT03375606: CSL730, Placebo.

Is NCT03375606 still recruiting?

NCT03375606 is currently terminated. Last updated 3 June 2021.

Last reviewed 2021-06-03 · How we verify

NCT03375606

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Assessing the Safety and Tolerability of CSL730 in Healthy Caucasian and Japanese Adults

Terminated Phase 1 Last updated 3 June 2021

What this trial tests

Phase 1 trial testing CSL730 in Healthy in 26 participants. Terminated before completion.

Timeline

10 January 2018

Primary endpoint
22 June 2020

22 June 2020

Quick facts

Lead sponsor	CSL Behring
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	quadruple
Primary purpose	other
Enrollment	26
Start date	10 January 2018
Primary completion	22 June 2020
Estimated completion	22 June 2020
Sites	2 locations across United Kingdom, Netherlands

Drugs / interventions tested

CSL730 — full drug profile →
Placebo

Conditions studied

Healthy — all drugs for Healthy →

Sponsor

CSL Behring — full company profile →

Who can join

Adults 20 to 55, any sex, with Healthy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To assess the safety and tolerability of ascending doses of CSL730 after a single intravenous (IV) infusion in healthy Caucasian and Japanese subjects

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Neonatal Fc Receptor-Targeted Therapies in Neurology.
Nelke C, Spatola M, Schroeter CB, Wiendl H, et al · · 2022 · cited 32× · PMID 34997443 · DOI 10.1007/s13311-021-01175-7

Verify or expand the search:

Other trials of CSL730

Trials testing the same drug.

NCT04446000 — Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CSL730 in Healthy Adult Subjec · Phase 1 · terminated

Other recruiting trials for Healthy

Currently open trials in the same condition.

NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting

Other CSL Behring trials

Trials by the same sponsor.

NCT07326592 — Phase 4, Double-blind Study Evaluating the Response on Computed Tomography (CT) Lung Density Decline Rates of Respreeza · Phase 4 · not yet recruiting
NCT07224360 — Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD) · Phase 2 · recruiting
NCT07332091 — Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary He · Phase 2 · recruiting
NCT07094087 — Efficacy and Safety of 4F-PCC (4-Factor Prothrombin Complex Concentrate) in Adult Patients Undergoing Complex Cardiovasc · Phase 3 · recruiting
NCT07048262 — Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults With Non-cystic Fibrosis Bronchiectasis (NC · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03375606 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by CSL Behring
Last refreshed: 3 June 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03375606.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing